Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT06534411 (REIMAGINE 5) for Diabetes Mellitus, Type 2 is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
Novo Nordisk A/SA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both (REIMAGINE 5) Phase 3 1,023
Clinical Trial NCT06534411 (REIMAGINE 5) is designed to study Treatment for Diabetes Mellitus, Type 2. It is a Phase 3 interventional study that is active, not recruiting, having started on November 5, 2024, with plans to enroll 1,023 participants. Led by Novo Nordisk A/S, it is expected to complete by July 14, 2026. The latest data from ClinicalTrials.gov was last updated on December 12, 2025.
Brief Summary
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is deci...Show More
Official Title
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both
Conditions
Diabetes Mellitus, Type 2Other Study IDs
- REIMAGINE 5
- NN9388-7741
- U1111-1300-2590 (Other Identifier) (World Health Organization (WHO))
- 2023-509600-15 (Other Identifier) (European Medical Agency (EMA))
NCT ID Number
Start Date (Actual)
2024-11-05
Last Update Posted
2025-12-12
Completion Date (Estimated)
2026-07-14
Enrollment (Estimated)
1,023
Study Type
Interventional
PHASE
Phase 3
Status
Active, not recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalCagriSema Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every 4 weeks in a 8-week dose escalation period until target dose of CagriSema is achieved and maintained for 52 weeks. | Cagrilintide Participants will receive once-weekly cagrilintide subcutaneously. Semaglutide Participants will receive once-weekly semaglutide subcutaneously. |
ExperimentalTirzepatide Participants will receive once-weekly s.c injections of tirzepatide at escalating dose in a 4-week dose escalating period and maintained up to 56 weeks. | Tirzepatide Participants will receive once-weekly tirzepatide subcutaneously. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in Glycated Haemoglobin (HbA1c) | Measured in percentage points. | From baseline (week 0) to end of treatment (week 60) |
Relative Change in Body Weight | Measured in percentage (%). | From baseline (week 0) to end of treatment (week 60) |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in HbA1c | Measured in percentage points. | From baseline (week 0) to end of treatment (week 60) |
Change in Fasting Plasma Glucose (FPG) | Measured as millimole per liter (mmol/L). | From baseline (week 0) to end of treatment (week 60) |
Number of Participants Who Achieve HbA1c Target Values of Less Than (<) 7.0 (Percent [%]) (< 53 millimole per mole [mmol/mol]) | Measured as count of participants. | At end of treatment (week 60) |
Number of Participants Who Achieve HbA1c Target Values of Less Than or Equal to (<=) 6.5% (<= 48 mmol/mol) | Measured as count of participants. | At end of treatment (week 60) |
Number of Participants Who Achieve Greater Than or Equal to (>=) 5% Weight Reduction | Measured as count of participants. | From baseline (week 0) to end of treatment (week 60) |
Number of Participants Who Achieve >= 10% Weight Reduction | Measured as count of participants. | From baseline (week 0) to end of treatment (week 60) |
Number of Participants Who Achieve >= 15% Weight Reduction | Measured as count of participants. | From baseline (week 0) to end of treatment (week 60) |
Number of Participants Who Achieve >= 20% Weight Reduction | Measured as count of participants. | From baseline (week 0) to end of treatment (week 60) |
Change in Systolic Blood Pressure (SBP) | Measured in millimeter of mercury (mmHg). | From baseline (week 0) to end of treatment (week 60) |
Change in Diastolic Blood Pressure (DBP) | Measured in mmHg. | From baseline (week 0) to end of treatment (week 60) |
Change in Waist Circumference | Measured in centimeter (cm). | From baseline (week 0) to end of treatment (week 60) |
Ratio to Baseline in Lipids: Total Cholesterol | Measured as ratio. | From baseline (week 0) to end of treatment (week 60) |
Ratio to Baseline in Lipids: High Density Lipoprotein (HDL) Cholesterol | Measured as ratio. | From baseline (week 0) to end of treatment (week 60) |
Ratio to Baseline in Lipids: Low Density Lipoprotein (LDL) Cholesterol | Measured as ratio. | From baseline (week 0) to end of treatment (week 60) |
Ratio to Baseline in Lipids: Very Low Density Lipoprotein (VLDL) Cholesterol | Measured as ratio. | From baseline (week 0) to end of treatment (week 60) |
Ratio to Baseline in Lipids: Triglycerides | Measured as ratio. | From baseline (week 0) to end of treatment (week 60) |
Ratio to Baseline in Lipids: Non-HDL cholesterol | Measured as ratio. | From baseline (week 0) to end of treatment (week 60) |
Change in Short Form (SF) -36v2 Score: Physical Component Summary Score | Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Physical component summary scores ranges from 6.1 to 79.7 with higher scores indicating better functional health and well-being. | From baseline (week 0) to end of treatment (week 60) |
Change in SF-36v2 Score: Mental Component Summary Score | Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Mental component summary scores ranges from -3.8 to 78.7 with higher scores indicating better functional health and well-being. | From baseline (week 0) to end of treatment (week 60) |
Change in SF-36v2 Score: Vitality Subscale | Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Vitality score ranges from 25.6 to 69.1 with higher scores indicating better functional health and well-being. | From baseline (week 0) to end of treatment (week 60) |
Change in Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQOL-Lite-CT) : Physical Function score | Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Physical functioning score ranges from 0 to 100, with higher scores reflecting better levels of functioning. | From baseline (week 0) to end of treatment (week 60) |
Change in IWQOL-Lite-CT: Total score | Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score ranges from 0 to 100, with higher scores reflecting better levels of functioning. | From baseline (week 0) to end of treatment (week 60) |
Number of Treatment Emergent Adverse Events (TEAEs) | Measured as count of events. | From baseline (week 0) to end of study (week 66) |
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (<54 Milligram per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter | Measured as count of episodes. | From baseline (week 0) to end of study (week 66) |
Number of Severe Hypoglycaemic Episodes (Level 3): Hypoglycaemia Associated With Severe Cognitive Impairment Requiring External Assistance for Recovery, With no Specific Glucose Threshold | Measured as count of episodes. | From baseline (week 0) to end of study (week 66) |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Male or female (sex at birth).
- Age 18 years or above at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal to (>=) 180 days before screening.
- Stable daily dose(s) >= 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:
- Metformin
- sodium-glucose co-transporter 2 inhibitor (SGLT2i)
- Glycated haemoglobin (HbA1c) 7.0-10.5 percent (53-91 millimoles per mol \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening.
- Body mass index (BMI) >= 30 kilogram per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
- Renal impairment with estimated Glomerular Filtration Rate less than < 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2) as determined by central laboratory at screening.
- Treatment with any anti-diabetic or anti-obesity medication (irrespective of indication) other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days is allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Novo Nordisk A/S131 active studies to exploreNo contact data.
163 Study Locations in 14 Countries
Alabama
Cahaba Research, Pelham, Alabama, 35124, United States
Arizona
Velocity Clinical Research-Phoenix, Phoenix, Arizona, 85006, United States
AES Tucson DRS, Tucson, Arizona, 85712, United States
Arkansas
Woodland Int. Research Group, Little Rock, Arkansas, 72211, United States
California
Velocity Clin Res-Chula Vista, Chula Vista, California, 91911, United States
John Muir Physicians Network, Concord, California, 94520, United States
Diabetes & Endocrine Specialists - La Mesa, La Mesa, California, 91942, United States
Velocity Clin Research LA, Los Angeles, California, 90017, United States
Desert Oasis Healthcare, Palm Springs, California, 92262, United States
Velocity Clin Res Santa Ana, Santa Ana, California, 92704, United States
Velocity Clin Res - Panorama, Van Nuys, California, 91405, United States
Colorado
Optumcare Clinical Trials,LLC-Golden, Colorado Springs, Colorado, 80906, United States
District of Columbia
FEME Medical LLC, Washington D.C., District of Columbia, 20010, United States
Florida
Tampa Bay Medical Research, Clearwater, Florida, 33761, United States
AGA Clinical Trial, Hialeah, Florida, 33012, United States
Clinical Trial Services Corp, Miami, Florida, 33144, United States
Bioclinical Research Alliance, Miami, Florida, 33155, United States
New Horizon Research Center, Miami, Florida, 33165, United States
South Broward Research LLC, Miramar, Florida, 33027, United States
West Orange Endocrinology, Ocoee, Florida, 34761, United States
Optimal Research Sites, Orange City, Florida, 32763, United States
Georgia
Javara Inc. / Privia Medical Group Georgia LLC, Fayetteville, Georgia, 30214, United States
Illinois
Clinical Invest Special_Gurnee, Gurnee, Illinois, 60031, United States
Iowa
Iowa Diabetes & Endo Res Ctr, West Des Moines, Iowa, 50266, United States
Kansas
Cotton-Oneill Diabetes and End, Topeka, Kansas, 66606-2806, United States
Minnesota
AES Minneapolis DRS, Richfield, Minnesota, 55423, United States
Mississippi
Velocity Clin Res Gulfport, Gulfport, Mississippi, 39503, United States
Missouri
AES St. Louis DRS, St Louis, Missouri, 63141, United States
Nebraska
Univ of Nebraska Medical CTR, Omaha, Nebraska, 68198-3020, United States
New Mexico
Velocity Clin Res Albuquerque, Albuquerque, New Mexico, 87107, United States
New York
Albany Medical College, Albany, New York, 12203, United States
North Carolina
Carteret Medical Group, Morehead City, North Carolina, 28557, United States
Piedmont Healthcare/Research, Statesville, North Carolina, 28625, United States
North Dakota
Lillestol Research LLC, Fargo, North Dakota, 58104, United States
Oklahoma
Triad Research Institute, Norman, Oklahoma, 73072, United States
Pennsylvania
Circuit Clinical - PMSI, Pottstown, Pennsylvania, 19464, United States
Rhode Island
Clinical Res Collaborative, Cumberland, Rhode Island, 02864, United States
Velocity Clin Res Providence, East Greenwich, Rhode Island, 02818, United States
South Carolina
Velocity Clin Res Gaffney, Gaffney, South Carolina, 29340, United States
Tennessee
Holston Medical Group, Kingsport, Tennessee, 37660, United States
Clinical Research Associates, Nashville, Tennessee, 37203, United States
Texas
Velocity Clin Res Austin, Austin, Texas, 78759, United States
AES Dallas DFW DRS, Dallas, Texas, 75234, United States
UT Southwestern Medical Center - Lingvay, Dallas, Texas, 75390, United States
JCCT- Juno NW Houston, Houston, Texas, 77040, United States
Discovery MM Services - Houston - Broadway Street, Houston, Texas, 77061, United States
PlanIt Research, PLLC, Houston, Texas, 77079, United States
Sante Clinical Research, Kerrville, Texas, 78028, United States
Aeres Clinical Research, Laredo, Texas, 78041, United States
RGV Endocrine Center, McAllen, Texas, 78503, United States
Privia Health Javara Clin Res., Stephenville, Texas, 76401, United States
Utah
J.Lewis Research Inc, Salt Lake City, Utah, 84109, United States
Chrysalis Clinical Research, St. George, Utah, 84790, United States
Virginia
TPMG Clinical Research, Newport News, Virginia, 23606, United States
British Columbia
Hilltop Medical Clinic, Surrey, British Columbia, V4A 0C1, Canada
New Brunswick
G.A. Research Associates Ltd., Moncton, New Brunswick, E1G 1A7, Canada
Ontario
Centricity Research Brampton, Brampton, Ontario, L6S 0C6, Canada
Centricity Research Etobicoke, Etobicoke, Ontario, M9R 4E1, Canada
Wharton Med Clin Trials, Hamilton, Ontario, L8L 5G8, Canada
London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, N7T 4X3, Canada
Diabetes Heart Research Centre, Toronto, Ontario, M6G 1M2, Canada
Quebec
Ctr de rech Clin de Laval, Laval, Quebec, H7T 2P5, Canada
Alpha Recherche Clinique - Clinique de Levis, Lévis, Quebec, G6V 0C9, Canada
Centre Medical Acadie, Montreal, Quebec, H4N 2W2, Canada
Ctr de Med Metab de Lanaudiere, Terrebonne, Quebec, J6X 4P7, Canada
Diex Recherche Victoriaville, Victoriaville, Quebec, G6P 3Z8, Canada
Centre de Recherche Saint-Louis, Québec, G1W 4R4, Canada
Buenos Aires
Centro Médico CIMEL, Lanús Este, Buenos Aires, B1824KAJ, Argentina
Centro de Investigaciones Médicas Mar del Plata, Mar del Plata, Buenos Aires, B7600GNY, Argentina
La Pampa Province
Fundación CESIM, Santa Rosa, La Pampa Province, 6300, Argentina
Tucumán Province
Centro de Investigaciones Médicas Tucumán, San Miguel de Tucuimán, Tucumán Province, 4000, Argentina
IMOBA, City of Buenos Aires, C1056ABH, Argentina
Centro de Investigaciones Metabólicas, City of Buenos Aires, C1056ABI, Argentina
Instituto de Investigaciones Clinicas San Nicolás, San Nicolás, B2900, Argentina
Australian Capital Territory
Paratus Clinical, Bruce, Australian Capital Territory, 2617, Australia
New South Wales
Hunter Diabetes Centre, Merewether, New South Wales, 2291, Australia
Austrials, St Leonards, New South Wales, 2065, Australia
Momentum Clinical Research, St Leonards, New South Wales, 2065, Australia
Roger Chih Yu Chen, Sydney, New South Wales, 2148, Australia
Queensland
Townsville University Hospital, Douglas, Queensland, 4814, Australia
Paratus Clinical, Herston, Queensland, 4006, Australia
Paraná
Centro de Diabetes Curitiba, Curitiba, Paraná, 80810-040, Brazil
Rio Grande do Sul
Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda., Porto Alegre, Rio Grande do Sul, 90430-001, Brazil
São Paulo
CPQuali Pesquisa Clínica Ltda, São Paulo, São Paulo, 01228-000, Brazil
Herz- und Diabeteszentrum NRW - Bad Oeynhausen, Bad Oeynhausen, 32545, Germany
Universitätsklinikum Essen - Klinik für Endokrinologie, Diabetologie und Stoffwechsel, Essen, 45147, Germany
Praxis am Markt Dr. Becker, Essen, 45355, Germany
Universitätsklinikum Freiburg - Innere Medizin II, Freiburg im Breisgau, 79106, Germany
Wendisch/Dahl Hamburg (DZHW), Hamburg, 22607, Germany
Medicover Neuroendokrinologie MVZ München, München, 81667, Germany
MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin, Münster, 48153, Germany
Zentrum für klinische Studien Allgäu Oberschwaben, Wangen, 88239, Germany
Attica
Alexandra General Hospital, Therapeutic Clinic, Athens, Attica, 11528, Greece
Crete
General Hospital Venizeleio-Pananeio - Diabetic Clinic, Heraklion, Crete, 71409, Greece
Evangelismos Hospital, Athens, 10676, Greece
Iatriko Athinon 'Palaiou Falirou', Athens, 17562, Greece
"Laiko" General Hospital of Athens, Goudi/Athens, 11527, Greece
University General Hospital of Ioannina,Internal Medicine, Ioannina, 45500, Greece
General Hospital of Thessaloniki 'G. Gennimatas, Thessaloniki, 54635, Greece
'Ippokrateio' General Hospital of Thessaloniki, Thessaloniki, 54642, Greece
Csongrád-Csanád
Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ, Szeged, Csongrád-Csanád, 6725, Hungary
Komárom-Esztergom
Komáromi Selye János Kórház, Komárom, Komárom-Esztergom, 2900, Hungary
Pest County
QUALICLINIC Egészségügyi Szolgáltató és Kutatásszervező Kft, Budapest, Pest County, 1036, Hungary
Óbudai Egészségügyi Centrum, Budapest, Pest County, 1036, Hungary
Szőcs Depot Egészségügyi Szolgáltató Kft., Budapest, 1042, Hungary
Semmelweis Egyetem, Budapest, 1083, Hungary
ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft., Budapest, 1089, Hungary
PVN Kutato Kft., Budapest, 1102, Hungary
MED-TIMA Kft., Budapest, 1132, Hungary
Észak-Pesti Centrumkórház Honvédkórház, Budapest, 1134, Hungary
Andhra Pradesh
Endolife Specialty Hospitals, Guntur, Andhra Pradesh, 522001, India
Karnataka
Ramaiah Memorial Hospital, Bengaluru, Karnataka, 560054, India
Maharashtra
Excel Endocrine Centre, Kolhāpur, Maharashtra, 416008, India
Acharya Vinoba Bhave Rural Hospital, Sawangi Meghe, Wardha, Wardha, Maharashtra, 442001, India
National Capital Territory of Delhi
All India Institute of Medical Sciences (AIIMS), New Delhi, National Capital Territory of Delhi, 110029, India
Rajasthan
Jawahar Lal Nehru Govt. Medical College, Ajmer, Rajasthan, 305001, India
SMS Hospital, Jaipur, Rajasthan, 302004, India
Diabetes, Thyroid and Endocrine Centre, Jaipur, Rajasthan, 302006, India
Tamil Nadu
Arthur Asirvatham hospital,, Madurai, Tamil Nadu, 625 020, India
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Tamil Nadu, 605006, India
Telangana
AIG Hospitals,Hyderabad, Hyderabad, Telangana, 500032, India
Uttar Pradesh
Udyaan Health Care, Lucknow, Uttar Pradesh, 226002, India
West Bengal
IPGME&R and SSKM Hospital, Kolkata, West Bengal, 700020, India
Israel
Clalit sick fund Herzeliya, Herzeliya, Israel, 4630945, Israel
Rambam MC - Diabetes and obesity center of excellence, Haifa, 31096, Israel
Wolfson MC - Diabetes Clinic, Holon, 58100, Israel
Hadassah Ein Karam MC - Diabetes Unit, Jerusalem, 91120, Israel
Rabin MC Beilinson - Endo unit, Petah Tikva, 49100, Israel
Sourasky MC - Institute of Endocrinology, metabolism and hypertension, Tel Aviv, 6423906, Israel
Sheba MC - Endocrinology Clinic, Tel Litwinsky, 52621, Israel
Podlaskie Voivodeship
Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Podlaskie Voivodeship, 15-276, Poland
Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, 15-269, Poland
Diab Serwis Popenda Spółka Jawna, Chorzów, 41-516, Poland
Specjalistyczny Gabinet Diabetologiczny Rumianowski Radosław, Gorzów Wielkopolski, 66-400, Poland
Centrum Terapii Wspolczesnej - J.M. Jasnorzewska S.K.A., Lodz, 90-338, Poland
Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A., Olsztyn, 10-117, Poland
Kiepury Clinic MALGORZATA JARNOT SPECJALISTYCZNA PRAKTYKA GINEKOLOGICZNO-POLOZNICZA, Sosnowiec, 41-209, Poland
Centrum Medyczne Oporow, Wroclaw, 52-416, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko, Zabrze, 41-800, Poland
Bihor County
Diabdana S.R.L., Oradea, Bihor County, 410147, Romania
Bucurestii
Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila, Bucharest, Bucurestii, 020475, Romania
Maramureş
CMI Dr Pop Lavinia, Baia Mare, Maramureş, 430222, Romania
Mureș County
Sc Mediab Srl, Târgu Mureş, Mureș County, 540142, Romania
SC Nutrilife SRL, Bucharest, 013764, Romania
Diabet Med SRL, Bucharest, 050913, Romania
Sanamed Hospital SRL, Bucharest, 060013, Romania
Clinica Korall S.R.L. Satu Mare, Satu Mare, 440055, Romania
Navarre
Clinica Universitaria de Navarra, Pamplona, Navarre, 31008, Spain
Centro Periferico De Especialidades Bola Azul, Almería, 04009, Spain
Hospital Vall d'Hebron, Barcelona, 08035, Spain
Hospital Universitario San Cecilio, Granada, 18016, Spain
Clínica Nuevas Tecnologías en Diabetes y Endocrinología, Seville, 41003, Spain
Hospital Clínico de Valladolid, Valladolid, 47003, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, 807, Taiwan
Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung City, 833, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaoshiung, 807, Taiwan
China Medical University Hospital, Taichung, 404328, Taiwan
China Medical University Hospital, Taichung, 404, Taiwan
Taichung Veterans General Hospital, Taichung, 407, Taiwan
National Cheng Kung University Hospital, Tainan, 704, Taiwan
Taipei Veterans General Hospital, Taipei, 112, Taiwan
Chang Gung Memorial Hospital Linkou, Taoyuan, 333, Taiwan
Chang Gung Memorial Hospital, Linkou, Taoyuan District, 333, Taiwan